PIK3CA R1023Q

CI-VAR-00003607Explore in graph →NP_006209.2:p.Arg1023GlnNM_006218.2:c.3068G>ACIViC 1594

Curated evidence

Evidence by cancer (1 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–1 of 1 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Malignant Colorectal Neoplasm1
PIK3CA R1023Q	Cetuximab	Predictive	C	Supports Resistance	—	rejected	EID4685 In a retrospective study of 168 chemotherapy-refractory metastatic colorectal cancer patients, patients with a PIK3CA mutation (n=26) treated with cetuximab in combination with standard chemotherapy, … (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.